Phase 2 N=99 RN624 For Pain Of Post-Herpetic Neuralgia
Neuralgia, Postherpetic
Primary: Change From Baseline in Average Daily Pain Numeric Rating Scale (NRS) Score at Week 6 — 6.40; 6.42; 6.39; -1.22 units on a scale — p=0.687
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
Colorectal Neoplasms · Melanoma · Prostatic Neoplasms
Primary: Safety Endpoints: Serious Adverse Events to Tremelimumab. — 4; 33 Participants
Phase 2 N=33 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium
Cervical Cancer · Endometrial Cancer
Primary: Proportion of Patients Who Are Progression-free at 6 Months — 0.29 Proportion of patients
Phase 2 N=180 Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Overall Survival — 8.8; 9.8 months — p=0.72
Phase 2 N=28 Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 5; 2; 0; 0 Participants
Phase 2 N=26 A Pilot Study of KPL-914 in Recurrent Pericarditis
Recurrent Pericarditis
Primary: Parts 1, 2 and 4: Pretreatment C-Reactive Protein (CRP) Levels — 5.921; 0.645; 4.455; 5.156 mg/dL
Phase 2 N=24 Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
Epilepsy
Primary: Area Under the Concentration Time Curve (AUC) 0 to 4 Hours Post-dose — 739.33; 585 hr*ng/mL
Phase 2 N=37 Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery
Sarcoma
Primary: Maximum Tolerated Dose (MTD) of Doxorubicin Hydrochloride Plus Pembrolizumab According to the National Cancer Institute (NCI) Common Terminology for Adverse Events…
Phase 2 N=51 A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
Idiopathic Pulmonary Fibrosis · Cough
Primary: Mixed Model of Repeated Measures (MMRM) Change From Baseline in Awake Objective Cough Frequency (Periods 1 & 2 Combined) — -9.1; -6.6; -6.6; -5.8 Coughs/hour — p=0.5096
Phase 2 N=183 Nigella Sativa in COVID-19
COVID-19 · SARS-CoV-2
Primary: Percentage of Participants With Clinical Recovery Within 14 Days After Randomization — 54; 31 Participants — p=0.001
Phase 2 N=58 Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
Lymphoma, Mantle- Cell
Primary: Overall Response Rate (ORR) — 8.6 percentage of participants
Phase 2 N=6 Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
Breast Cancer
Primary: Number of Participants Experiencing Adverse Events — 6 Participants
Phase 2 N=38 Treating Smokers With Mental Illness
Smoking Cessation · Cigarette Smoking · Schizophrenia
Primary: 7-Day Point Prevalence Abstinence — 5; 3; 4; 5 Participants
Phase 2 N=120 SGI-110 in Combination With Carboplatin in Ovarian Cancer
Ovarian Cancer
Primary: Stage 1: Dose Limiting Toxicities — 0; 4 Participants
Phase 2 N=22 Sequential Therapy for the Treatment of Severe Bipolar Depression.
Bipolar Depression · Suicidal Ideas · Suicidal Ideation
Primary: BDM Score (BISS-derived MADRS) Change From Baseline at Day 42 — 3.3; 2.4; -1.06; 0 score on a scale — p=.03